BG108193A - Pregabalin lactose conjugates - Google Patents

Pregabalin lactose conjugates

Info

Publication number
BG108193A
BG108193A BG108193A BG10819303A BG108193A BG 108193 A BG108193 A BG 108193A BG 108193 A BG108193 A BG 108193A BG 10819303 A BG10819303 A BG 10819303A BG 108193 A BG108193 A BG 108193A
Authority
BG
Bulgaria
Prior art keywords
disorders
pregabalin lactose
pregabalin
disease
subject
Prior art date
Application number
BG108193A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael J. Lovdahl
Timothy R. Hurley
Brian Tobias
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG108193A publication Critical patent/BG108193A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG108193A 2001-03-30 2003-09-24 Pregabalin lactose conjugates BG108193A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28017601P 2001-03-30 2001-03-30
PCT/IB2002/000647 WO2002078747A2 (en) 2001-03-30 2002-02-25 Pregabalin lactose conjugates

Publications (1)

Publication Number Publication Date
BG108193A true BG108193A (en) 2004-09-30

Family

ID=23072002

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108193A BG108193A (en) 2001-03-30 2003-09-24 Pregabalin lactose conjugates

Country Status (32)

Country Link
US (1) US7022678B2 (enExample)
EP (1) EP1377318A2 (enExample)
JP (1) JP2004524357A (enExample)
KR (1) KR20040008146A (enExample)
CN (1) CN1511043A (enExample)
AP (1) AP2003002873A0 (enExample)
AR (1) AR033024A1 (enExample)
BG (1) BG108193A (enExample)
BR (1) BR0208439A (enExample)
CA (1) CA2440468C (enExample)
CZ (1) CZ20032547A3 (enExample)
DO (1) DOP2002000356A (enExample)
EA (1) EA200300954A1 (enExample)
EC (1) ECSP034740A (enExample)
EE (1) EE200300480A (enExample)
GT (1) GT200200051A (enExample)
HU (1) HUP0303956A2 (enExample)
IL (1) IL157879A0 (enExample)
IS (1) IS6912A (enExample)
MA (1) MA27004A1 (enExample)
MX (1) MXPA03007437A (enExample)
NO (1) NO20034348D0 (enExample)
OA (1) OA12456A (enExample)
PA (1) PA8542101A1 (enExample)
PE (1) PE20021016A1 (enExample)
PL (1) PL369179A1 (enExample)
SK (1) SK11832003A3 (enExample)
SV (1) SV2003000928A (enExample)
TN (1) TNSN02038A1 (enExample)
UY (1) UY27233A1 (enExample)
WO (1) WO2002078747A2 (enExample)
ZA (1) ZA200306608B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693258B2 (ja) 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルgabaまたはその誘導体を含有する鎮静剤
CA2619472A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US20100087525A1 (en) * 2008-06-23 2010-04-08 Lilach Hedvati Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
WO2010115612A2 (en) 2009-04-10 2010-10-14 Synthon B.V. Pregabalin compositions
WO2010150221A1 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Taste masked pharmaceutical compositions of pregabalin
HU230031B1 (hu) * 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
CN104311608B (zh) * 2014-10-28 2016-10-05 河南中烟工业有限责任公司 亲水型烟草增香保润剂Mal-Hyp、制备方法及其应用
CN104370986B (zh) * 2014-10-28 2017-07-04 河南中烟工业有限责任公司 糖衍生物烟用增香保润剂Mal‑Pro、制备方法及其应用
CN105434395B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊及其制备方法
CN105520918B (zh) * 2015-12-31 2018-12-11 常州市阳光药业有限公司 普瑞巴林胶囊

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
NZ510920A (en) * 1998-10-16 2002-08-28 Warner Lambert Co Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
WO2002043762A2 (en) * 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
KR20040008146A (ko) 2004-01-28
NO20034348L (no) 2003-09-29
SK11832003A3 (sk) 2004-04-06
WO2002078747A9 (en) 2003-12-31
BR0208439A (pt) 2004-03-23
MXPA03007437A (es) 2003-11-18
WO2002078747A2 (en) 2002-10-10
AP2003002873A0 (en) 2003-09-30
ZA200306608B (en) 2004-11-25
CZ20032547A3 (en) 2004-04-14
CA2440468A1 (en) 2002-10-10
US7022678B2 (en) 2006-04-04
EP1377318A2 (en) 2004-01-07
HUP0303956A2 (hu) 2004-04-28
GT200200051A (es) 2002-11-15
US20020187941A1 (en) 2002-12-12
CA2440468C (en) 2008-09-02
NO20034348D0 (no) 2003-09-29
IL157879A0 (en) 2004-03-28
PE20021016A1 (es) 2002-11-14
MA27004A1 (fr) 2004-12-20
EA200300954A1 (ru) 2004-02-26
ECSP034740A (es) 2003-12-24
CN1511043A (zh) 2004-07-07
PL369179A1 (en) 2005-04-18
EE200300480A (et) 2003-12-15
PA8542101A1 (es) 2002-10-28
OA12456A (en) 2004-08-24
WO2002078747A3 (en) 2003-10-09
DOP2002000356A (es) 2002-12-15
TNSN02038A1 (fr) 2005-12-23
WO2002078747A8 (en) 2003-12-04
AR033024A1 (es) 2003-12-03
IS6912A (is) 2003-08-14
UY27233A1 (es) 2002-10-31
SV2003000928A (es) 2003-07-29
JP2004524357A (ja) 2004-08-12

Similar Documents

Publication Publication Date Title
BG108193A (en) Pregabalin lactose conjugates
WO2002004451A3 (en) Methods for stimulation of synthesis of synaptophysin in the central nervous system
EP1602369A3 (en) Bupropion Metabolites and Methods of their Synthesis and Use
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
YU30004A (sh) Upotreba flibanserina u lečenju seksualnih poremećaja
BRPI0316438C1 (pt) uso de eritropoietina em doenças cardíacas
MX348062B (es) Mutantes que degradan proteoglicanos para tratamiento del snc.
MY135838A (en) Methods for the treatment of mental disorders
EA200301063A1 (ru) Фармацевтические агенты для лечения ганв и микроаденом
SI1553985T1 (sl) Bifenili kot sredstva za slikanje pri Alzheimerjevi bolezni
JO2260B1 (en) Piperidine ethanesulfonyl derivatives
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
ES2144698T3 (es) Procedimiento para preparar un derivado de biciclohexano.
EP1192943A3 (en) Use of growth hormone secretagogues in conjunction with physical exercise
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
CR7060A (es) Conjugados de pregabalina-lactosa
WO2004062610A3 (en) 4',4''-SUBSTITUTED 3α-(DIPHENYLMETHOXY)TROPANE ANALOGS FOR TREATMENT OF MENTAL DISORDERS
UA94044C2 (ru) Применение бензоильного производного 3-аминокарбазола для лечения нарушения, связанного с производством простагландина e2 (pge2)
WO2002015841A3 (fr) Composition pharmaceutique comprenant la selegiline pour le traitement des dysfonctions sexuelles
EA200501282A1 (ru) Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом